{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T13:22:20Z","timestamp":1768483340443,"version":"3.49.0"},"reference-count":32,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,3,1]],"date-time":"2018-03-01T00:00:00Z","timestamp":1519862400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,3,1]],"date-time":"2018-03-01T00:00:00Z","timestamp":1519862400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T00:00:00Z","timestamp":1551398400000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","seizure-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seizure"],"published-print":{"date-parts":[[2018,3]]},"DOI":"10.1016\/j.seizure.2018.01.018","type":"journal-article","created":{"date-parts":[[2018,2,2]],"date-time":"2018-02-02T14:55:21Z","timestamp":1517583321000},"page":"20-25","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":27,"special_numbering":"C","title":["Safety of antiepileptic drugs in children and young people: A prospective cohort study"],"prefix":"10.1016","volume":"56","author":[{"given":"Oluwaseun","family":"Egunsola","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Imti","family":"Choonara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Helen M.","family":"Sammons","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William P.","family":"Whitehouse","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.seizure.2018.01.018_bib0005","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1056\/NEJM200002033420503","article-title":"Early identification of refractory epilepsy","volume":"342","author":"Kwan","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1016\/j.seizure.2018.01.018_bib0010","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1016\/S1474-4422(12)70153-9","article-title":"Adverse effects of antiepileptic drugs","volume":"11","author":"Perucca","year":"2012","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.seizure.2018.01.018_bib0015","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1111\/j.1528-1167.2007.01041.x","article-title":"Idiosyncratic adverse reactions to antiepileptic drugs","volume":"48","author":"Zaccara","year":"2007","journal-title":"Epilepsia"},{"key":"10.1016\/j.seizure.2018.01.018_bib0020","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S0920-1211(02)00182-1","article-title":"Overtreatment in epilepsy: adverse consequences and mechanisms","volume":"52","author":"Perucca","year":"2002","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.seizure.2018.01.018_bib0025","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/S0920-1211(02)00183-3","article-title":"Overtreatment in children with epilepsy","volume":"52","author":"Holmes","year":"2002","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.seizure.2018.01.018_bib0030","article-title":"Monotherapy or polytherapy for childhood epilepsies?","author":"Egunsola","year":"2015","journal-title":"Arch Dis Child"},{"key":"10.1016\/j.seizure.2018.01.018_bib0035","series-title":"United Kingdom collaborative clinical audit of health care for children and young people with suspected epileptic seizures","author":"Royal College of Paediatrics and Child Health","year":"2012"},{"key":"10.1016\/j.seizure.2018.01.018_bib0040","doi-asserted-by":"crossref","first-page":"e008298","DOI":"10.1136\/bmjopen-2015-008298","article-title":"A prospective study of adverse drug reactions to antiepileptic drugs in children","volume":"5","author":"Anderson","year":"2015","journal-title":"BMJ Open"},{"key":"10.1016\/j.seizure.2018.01.018_bib0045","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1097\/WNF.0b013e31829a498d","article-title":"Adverse effects of antiepileptic drugs in North Indian pediatric outpatients","volume":"36","author":"Bansal","year":"2013","journal-title":"Clin Neuropharmacol"},{"key":"10.1016\/j.seizure.2018.01.018_bib0050","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1111\/j.1742-1241.1988.tb08497.x","article-title":"Anticonvulsant toxicity in paediatric out-patients","volume":"42","author":"Choonara","year":"1988","journal-title":"Br J Clin Pract"},{"key":"10.1016\/j.seizure.2018.01.018_bib0055","doi-asserted-by":"crossref","first-page":"519","DOI":"10.2165\/11630700-000000000-00000","article-title":"Safety and tolerability of antiepileptic drug treatment in children with epilepsy","volume":"35","author":"Guerrini","year":"2012","journal-title":"Drug Saf"},{"key":"10.1016\/j.seizure.2018.01.018_bib0060","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1056\/NEJM199209103271104","article-title":"A comparison of valproate with carbamazepine for the treatment of complex partial seizures and secondarily generalized tonic\u2013clonic seizures in adults","volume":"327","author":"Mattson","year":"1992","journal-title":"N Engl J Med"},{"key":"10.1016\/j.seizure.2018.01.018_bib0065","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1212\/WNL.0b013e3182635b87","article-title":"Development and validation of the pediatric epilepsy side effects questionnaire","volume":"79","author":"Morita","year":"2012","journal-title":"Neurology"},{"key":"10.1016\/j.seizure.2018.01.018_bib0070","doi-asserted-by":"crossref","first-page":"e28096","DOI":"10.1371\/journal.pone.0028096","article-title":"Development and inter-rater reliability of the Liverpool adverse drug reaction causality assessment tool","volume":"6","author":"Gallagher","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.seizure.2018.01.018_bib0075","doi-asserted-by":"crossref","first-page":"739","DOI":"10.2165\/00023210-200822090-00003","article-title":"CNS adverse events associated with antiepileptic drugs","volume":"22","author":"Kennedy","year":"2008","journal-title":"CNS Drugs"},{"key":"10.1016\/j.seizure.2018.01.018_bib0080","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/S1474-4422(04)00906-8","article-title":"Chronic epilepsy and cognition","volume":"3","author":"Elger","year":"2004","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.seizure.2018.01.018_bib0085","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/S0140-6736(00)03600-X","article-title":"Neuropsychological effects of epilepsy and antiepileptic drugs","volume":"357","author":"Kwan","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.seizure.2018.01.018_bib0090","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.ejpn.2007.09.004","article-title":"Add-on levetiracetam in children and adolescents with refractory epilepsy: results of an open-label multi-centre study","volume":"12","author":"Callenbach","year":"2008","journal-title":"Eur J Paediatr Neurol"},{"key":"10.1016\/j.seizure.2018.01.018_bib0095","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1111\/j.1528-1167.2008.01981.x","article-title":"Adjunctive levetiracetam in infants and young children with refractory partial\u00f1onset seizures","volume":"50","author":"Pi\u00f1a-Garza","year":"2009","journal-title":"Epilepsia"},{"key":"10.1016\/j.seizure.2018.01.018_bib0100","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1046\/j.1528-1157.2002.13101.x","article-title":"Efficacy and safety of levetiracetam in children with partial seizures: an open-label trial","volume":"43","author":"Glauser","year":"2002","journal-title":"Epilepsia"},{"key":"10.1016\/j.seizure.2018.01.018_bib0105","unstructured":"UCB Pharma limited. Keppra 250,500,750 and 1000\u202fmg film-coated Tablets, 100\u202fmg\/ml oral solution and 100\u202fmg\/ml concentrate for solution for infusion: Available at: https:\/\/www.medicines.org.uk\/emc\/medicine\/16231. May 9, 2016."},{"key":"10.1016\/j.seizure.2018.01.018_bib0110","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.seizure.2004.10.004","article-title":"Clinical experience with levetiracetam in childhood epilepsy: an add-on and mono-therapy trial","volume":"14","author":"Lagae","year":"2005","journal-title":"Seizure"},{"key":"10.1016\/j.seizure.2018.01.018_bib0115","doi-asserted-by":"crossref","first-page":"26","DOI":"10.26815\/jkcns.2011.19.1.26","article-title":"Levetiracetam monotherapy in children with epilepsy","volume":"19","author":"Sim","year":"2011","journal-title":"J Korean Child Neurol Soc"},{"key":"10.1016\/j.seizure.2018.01.018_bib0120","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.pediatrneurol.2006.09.018","article-title":"Levetiracetam monotherapy in children with epilepsy","volume":"36","author":"Khurana","year":"2007","journal-title":"Pediatr Neurol"},{"key":"10.1016\/j.seizure.2018.01.018_bib0125","doi-asserted-by":"crossref","first-page":"e0149686","DOI":"10.1371\/journal.pone.0149686","article-title":"Safety of levetiracetam in paediatrics: a systematic review","volume":"11","author":"Egunsola","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.seizure.2018.01.018_bib0130","doi-asserted-by":"crossref","first-page":"2376","DOI":"10.1007\/s00415-012-6509-3","article-title":"Prevalence, utilization, and costs of antiepileptic drugs for epilepsy in Germany\u2014a nationwide population-based study in children and adults","volume":"259","author":"Hamer","year":"2012","journal-title":"J Neurol"},{"key":"10.1016\/j.seizure.2018.01.018_bib0135","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1111\/j.1365-2125.2006.02842.x","article-title":"Prioritizing children's medicines for research: a pharmacoepidemiological study of antiepileptic drugs","volume":"63","author":"Ackers","year":"2007","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.seizure.2018.01.018_bib0140","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.pediatrneurol.2008.09.021","article-title":"First-drug treatment failures in children newly diagnosed with epilepsy","volume":"40","author":"Dudley","year":"2009","journal-title":"Pediatr Neurol"},{"key":"10.1016\/j.seizure.2018.01.018_bib0145","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1001\/archneur.55.5.668","article-title":"Epilepsy in childhood: an audit of clinical practice","volume":"55","author":"Carpay","year":"1998","journal-title":"Arch Neurol"},{"key":"10.1016\/j.seizure.2018.01.018_bib0150","doi-asserted-by":"crossref","first-page":"e007711","DOI":"10.1136\/bmjopen-2015-007711","article-title":"Safety of lamotrigine in paediatrics: a systematic review","volume":"5","author":"Egunsola","year":"2015","journal-title":"BMJ open."},{"key":"10.1016\/j.seizure.2018.01.018_bib0155","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1111\/j.1528-1157.1998.tb01361.x","article-title":"Commission on outcome measurement in epilepsy, 1994\u20131997: final report","volume":"39","author":"Baker","year":"1998","journal-title":"Epilepsia"},{"key":"10.1016\/j.seizure.2018.01.018_bib0160","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.socec.2010.10.008","article-title":"A literature review of the anchoring effect","volume":"40","author":"Furnham","year":"2011","journal-title":"J Socio-Econ"}],"container-title":["Seizure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1059131117308476?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1059131117308476?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T01:49:25Z","timestamp":1761011365000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1059131117308476"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3]]},"references-count":32,"alternative-id":["S1059131117308476"],"URL":"https:\/\/doi.org\/10.1016\/j.seizure.2018.01.018","relation":{},"ISSN":["1059-1311"],"issn-type":[{"value":"1059-1311","type":"print"}],"subject":[],"published":{"date-parts":[[2018,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety of antiepileptic drugs in children and young people: A prospective cohort study","name":"articletitle","label":"Article Title"},{"value":"Seizure","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.seizure.2018.01.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 British Epilepsy Association. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}